Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact
Uta Oelschlaegel(University Hospital Carl Gustav Carus), Uwe Platzbecker(National Center for Tumor Diseases), Martin Bornhaeuser(German Cancer Research Center), Lorenz Oelschlaeger(University Hospital Carl Gustav Carus), Frank Kroschinsky(University Hospital Carl Gustav Carus), Katja Sockel(Innsbruck Medical University), Malte von Bonin(Städtisches Klinikum Dresden), Lisa Wagenfuehr(University Hospital Carl Gustav Carus), Brigitte Mohr(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Michael Krämer(University Hospital Carl Gustav Carus)
Cited by 26
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402